Compact type II-C Cas9 nucleases with expanded PAM access and high fidelity for therapeutic genome editing
Compact type II-C Cas9 nucleases are attractive for therapeutic genome editing because their small size enables packaging into adeno-associated viral (AAV) vectors, and their extended protospacer-adjacent motifs (PAMs) reduce off-target cleavage while expanding targeting scope. Yet characterized type II-C orthologs have edited mammalian cells far less efficiently than the canonical SpCas9. Here,…
We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.
